BMY (Bristol-Myers Squibb Co.)
Insider Trading Activity
Every open-market purchase and sale reported by BMY officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Bartie Wendy Short | EVP, Corporate Affairs | MIXED | — | — |
| 2026-08-26 | Phil M Holzer | SVP and Controller | Sell | — | — |
| 2026-08-04 | Cristian Massacesi | EVP,Chief Med Offr,Head of Dev | MIXED | — | — |
| 2026-08-04 | Cari Gallman | EVP, General Counsel | MIXED | — | — |
| 2026-07-02 | PHYLLIS R YALE | Director | A | — | — |
| 2026-07-02 | Derica W Rice | Director | A | — | — |
| 2026-07-02 | Michael R. McMullen | Director | A | — | — |
| 2026-07-02 | Theodore R. Samuels II | Director | A | — | — |
| 2026-07-02 | Peter J Arduini | Director | A | — | — |
| 2026-06-16 | Julia A Haller | Director | M | — | — |
| 2026-06-05 | Bartie Wendy Short | EVP, Corporate Affairs | MIXED | — | — |
| 2026-05-05 | Adam Lenkowsky | EVP, Chief Commercial Officer | MIXED | — | — |
| 2026-04-02 | Peter J Arduini | Director | A | — | — |
| 2026-04-02 | Michael R. McMullen | Director | A | — | — |
| 2026-04-02 | Derica W Rice | Director | A | — | — |
| 2026-04-02 | Theodore R. Samuels II | Director | A | — | — |
| 2026-04-02 | PHYLLIS R YALE | Director | A | — | — |
| 2026-04-02 | David V Elkins | EVP, Chief Financial Officer | Sell | — | — |
| 2026-04-02 | Karin Shanahan | EVP, Chief Supply Chain & Ops | MIXED | — | — |
| 2026-03-12 | David V Elkins | EVP, Chief Financial Officer | MIXED | — | — |
| 2026-03-12 | CHRISTOPHER S. BOERNER | Chief Executive Officer | MIXED | — | — |
| 2026-03-12 | Ahn Amanda Poole | EVP, Chief People Officer | MIXED | — | — |
| 2026-03-12 | Cari Gallman | EVP, General Counsel | MIXED | — | — |
| 2026-03-12 | Lynelle Hoch | President, Cell Therapy Org. | MIXED | — | — |
| 2026-03-12 | Phil M Holzer | SVP and Controller | MIXED | — | — |
| 2026-03-12 | Adam Lenkowsky | EVP, Chief Commercial Officer | MIXED | — | — |
| 2026-03-12 | Gregory Scott Meyers | EVP, Chief Digital & Tech Off. | MIXED | — | — |
| 2026-03-12 | Robert M Plenge | EVP, Chief Research Officer | MIXED | — | — |
| 2026-03-12 | Karin Shanahan | EVP, Chief Supply Chain & Ops | MIXED | — | — |
| 2026-03-12 | Bartie Wendy Short | EVP, Corporate Affairs | MIXED | — | — |
| 2026-03-12 | Cristian Massacesi | EVP,Chief Med Offr,Head of Dev | A | — | — |
| 2026-03-12 | Hiroshi Chris Shibutani | EVP, Chief Strategy Officer | A | — | — |
| 2026-03-12 | Benjamin Hickey | President, RayzeBio Org. | A | — | — |
| 2026-03-03 | Benjamin Hickey | President, RayzeBio Org. | MIXED | — | — |
| 2026-02-03 | Peter J Arduini | Director | A | — | — |
| 2026-02-03 | Deepak Bhatt | Director | A | — | — |
| 2026-02-03 | Julia A Haller | Director | A | — | — |
| 2026-02-03 | Medina Manuel Hidalgo | Director | A | — | — |
| 2026-02-03 | Michael R. McMullen | Director | A | — | — |
| 2026-02-03 | Paula A Price | Director | A | — | — |
| 2026-02-03 | Derica W Rice | Director | A | — | — |
| 2026-02-03 | Theodore R. Samuels II | Director | A | — | — |
| 2026-02-03 | Karen H Vousden | Director | A | — | — |
| 2026-02-03 | PHYLLIS R YALE | Director | A | — | — |
| 2026-02-03 | Benjamin Hickey | President, RayzeBio Org. | MIXED | — | — |
| 2026-02-03 | Gregory Scott Meyers | EVP, Chief Digital & Tech Off. | MIXED | — | — |
| 2026-01-05 | Peter J Arduini | Director | A | — | — |
| 2026-01-05 | Michael R. McMullen | Director | A | — | — |
| 2026-01-05 | Derica W Rice | Director | A | — | — |
| 2026-01-05 | Theodore R. Samuels II | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 1,152,571 | — |
| — | SVP ComOps Pres USJap Int | 534,481 | — |
| — | EVP, General Counsel | 457,732 | — |
| — | Executive Chair of the Board | 400,946 | — |
| — | EVP, Head of Integration | 400,498 | — |
| — | EVP & CSO | 346,769 | — |
| — | EVP, Chief Information Officer | 210,977 | — |
| — | EVP Commercial Operations | 177,117 | — |
| — | Chief Executive Officer | 172,821 | — |
| — | EVP, Chief Financial Officer | 164,023 | — |
| — | EVP, CSO & President R&D | 157,312 | — |
| — | SVP HR Public Affairs & Philan | 151,611 | — |
| — | EVP & CFO | 147,338 | — |
| — | SVP Global Dev & Med Affairs | 94,374 | — |
| — | EVP,Chief Med.Offr.,Drug Dev. | 83,513 | — |
| — | Director | 79,851 | — |
| — | SVP, Human Resources | 74,828 | — |
| — | EVP, Investor Relations | 70,945 | — |
| — | EVP, Chief Commercial Officer | 50,167 | — |
| — | EVP and President, Hematology | 48,515 | — |
| — | EVP & President, Research | 48,406 | — |
| — | SVP Strat Transactions | 48,393 | — |
| — | SVP & Controller | 48,076 | — |
| — | Chief Compliance & Ethics Off | 38,810 | — |
| — | Director | 35,500 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BMY quote page; the site-wide leaderboard is on the insider transactions hub.